This advice takes account of the benefits of Patient Access Schemes (PAS) that improve the cost-effectiveness of trametinib and dabrafenib. This advice is contingent upon the continuing availability of these patient access schemes in NHS Scotland or list prices that are equivalent or lower.
NICE has also previously issued guidance recommending trametinib in combination with dabrafenib, within its marketing authorisation, as an option for treating unresectable or metastatic melanoma in adults with a BRAF V600 mutation only when the company provides trametinib and dabrafenib with the discounts agreed in the patient access schemes.